

Gastroenterology

www.gastrojournal.org

Vol. 154, No. 3

February 2018

TABLE OF
CONTENTS

Contents

ON THE COVER



Please see Memic et al on page 624 and editorial by M. D. Gershon on page 478 for further information.

GASTROENTEROLOGY'S DIAMOND ANNIVERSARY: 1943–2018

- 453** Viral Hepatitis: Knowledge and Treatments for Hepatitis B and C Virus and Associated Transplantation and Neoplasia
K. E. Sherman and V. H. Shah

COVERING THE COVER

- 457** *A. T. Chan and C. S. Williams*

COMMENTARIES

- 460** State of the Journal: *CMGH's* Progress, Prospects, and Impact Factor
J. R. Turner, J. R. Goldenring, M. Rescigno, and R. G. Wells
- 462** Update on the Use of Vonoprazan: A Competitive Acid Blocker
D. Y. Graham and M. P. Dore

MENTORING, EDUCATION, AND TRAINING CORNER

- 467** How to Obtain Training in Nutrition During the Gastroenterology Fellowship
D. Micic, E. K. McDonald, A. C. Stein, and C. E. Semrad

EDITORIALS

- 471** Nonceliac Gluten Sensitivity: What Is the Culprit?
K. Verbeke
See Skodje GI et al on page 529.
- 473** Colonoscopy Risks: What Is Known and What Are the Next Steps?
C. W. Ko
See Wang L et al on page 540.

 Video  Related article in *CGH*  Hot Papers From New Investigators

 CME quiz  Editorial accompanies this article  Additional online content available  Cover

Publisher: *Gastroenterology* (ISSN 0016-5085) is published monthly (semi monthly in January and May) in two indexed volumes by Elsevier Inc, 230 Park Avenue, New York, NY 10169-0901, USA. Periodicals postage paid at New York, NY and additional mailing offices. **POSTMASTER:** Send address changes to Elsevier, Journal Returns, 1799 Highway 50 East, Linn, MO 65051, USA. 2018 US subscription rates: individual, \$711.00; student and resident, \$271.00. Outside of the U.S. and possessions: individual, \$968.00; student and resident, \$562.00; surface delivery, no additional charge; air mail delivery, add \$78.00. Prices subject to change without notice.

- 475 **Intraductal Papillary Mucinous Neoplasm as the Focus for Early Detection of Pancreatic Cancer**
M. Tanaka
See Han Y et al on page 576.
- 478 **Development of the Enteric Nervous System: A Genetic Guide to the Perplexed**
M. D. Gershon
See Memic F et al on page 624.
- 481 **NVR 3-778 Plus Pegylated Interferon- α Treatment for Chronic Hepatitis B Viral Infections: Could 1 + 1 = 3?**
J. E. Tavis and E. Lomonosova
See Klumpp K et al on page 652.
- 482 **Pancreatitis: A Tale of Two Proteases**
A. Nikam, R. Dawra, A. Saluja, and V. Dudeja
See Sandler M et al on page 704.

GASTROENTEROLOGY IN MOTION

- 485 **Noninvasive Diagnosis of Pancreatic Cancer Through Detection of Volatile Organic Compounds in Urine**
R. P. Arasaradnam, A. Wicaksono, H. O'Brien, H. M. Kocher, J. A. Covington, and T. Crnogorac-Jurcevic

CLINICAL CHALLENGES AND IMAGES IN GI

- 488 **An Unexpected Cause of Recurrent Melena**
L. Ye, S. Jiang, and B. Hu
- 491 **Unexpected Findings in a Patient With Cancer of Unknown Primary Syndrome**
C. Lübbert and B. Holler
- 493 **Hepatic Mass in a Patient With Bladder Cancer History**
N. Horvat, M. Ragucci, and L. Mannelli
- 495 **Persistent Fever and Abdominal Pain in a Young Woman With Budd-Chiari Syndrome**
E. Liverani, A. Colecchia, and G. Mazzella

ELECTRONIC CLINICAL CHALLENGES AND IMAGES IN GI

For a full list, please see the table of contents online at www.gastrojournal.org.

PRACTICAL TEACHING CASE

- 498 **The Role of Anchoring in Working Up Diarrhea: A Practical Teaching Case**
C. L. Jansson-Knodell and S. Khanna

REVIEWS AND PERSPECTIVES

Reviews in Basic and Clinical Gastroenterology and Hepatology

- 500 **Mechanisms of Damage to the Gastrointestinal Tract From Nonsteroidal Anti-Inflammatory Drugs**
I. Bjarnason, C. Scarpignato, E. Holmgren, M. Olszewski, K. D. Rainsford, and A. Lanas

ORIGINAL RESEARCH

Brief Report

- 515** **Levels of Cytokines in Serum Associate With Development of Hepatocellular Carcinoma in Patients With HCV Infection Treated With Direct-Acting Antivirals**
J. D. Debes, M. van Tilborg, Z. M. A. Groothuisink, B. E. Hansen, J. Schulze zur Wiesch, J. von Felden, R. J. de Knegt, and A. Boonstra

The authors found a signature of immune markers in serum of patients, that predicts liver cancer development after treatment of hepatitis C virus.

Full Reports

Clinical—Alimentary Tract

- 518** **Incidence and Treatment of Patients Diagnosed With Inflammatory Bowel Diseases at 60 Years or Older in Sweden**

Å. H. Everhov, J. Halfvarson, P. Myrelid, M. C. Sachs, C. Nordenvall, J. Söderling, A. Ekblom, M. Neovius, J. F. Ludvigsson, J. Askling, and O. Olén

Elderly onset IBD in Sweden was associated with a lower use of biologics and immunomodulators and a higher absolute risk of bowel surgery compared to younger patients.

- 529** **Fructan, Rather Than Gluten, Induces Symptoms in Patients With Self-Reported Non-Celiac Gluten Sensitivity**

G. I. Skodje, V. K. Sarna, I. H. Minelle, K. L. Rolfsen, J. G. Muir, P. R. Gibson, M. B. Veierød, C. Henriksen, and K. E. A. Lundin

See editorial on page 471.

In this randomized, double-blind, placebo-controlled crossover study of individuals with self-reported non-celiac gluten sensitivity, the authors found fructans to induce symptoms, measured by the gastrointestinal symptom rating scale irritable bowel syndrome version.

- 540** **Low Rates of Gastrointestinal and Non-Gastrointestinal Complications for Screening or Surveillance Colonoscopies in a Population-Based Study**

L. Wang, A. Mannalithara, G. Singh, and U. Ladabaum

See editorial on page 473.

The risks of heart attack, stroke and other non-GI complications after screening colonoscopy are similar to those after other minimally invasive procedures; thus, they may not significantly exceed the baseline risks in the general population.

- 556** **Cost Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer**

A. Gini, A. G. Zauber, D. R. Cenin, A.-H. Omidvari, S. E. Hempstead, A. K. Fink, A. B. Lowenfels, and I. Lansdorp-Vogelaar

This study provides important guidance to clinicians, researchers, and policy makers who aim to define a tailored colorectal cancer screening for patients with Cystic Fibrosis. This analysis shows that screening in these individuals is cost-effective.

- 568** **Accurate Classification of Diminutive Colorectal Polyps Using Computer-Aided Analysis**

P.-J. Chen, M.-C. Lin, M.-J. Lai, J.-C. Lin, H. H.-S. Lu, and V. S. Tseng

Computer-aided analysis with a deep neural network can accurately classify magnifying narrow-band images of diminutive colorectal polyps as neoplastic or hyperplastic, and is not inferior to the human eyes of experts.

Clinical—Pancreas

- 576** **Progression of Pancreatic Branch Duct Intraductal Papillary Mucinous Neoplasm Associates With Cyst Size**

Y. Han, H. Lee, J. S. Kang, J. R. Kim, H. S. Kim, J. M. Lee, K.-B. Lee, W. Kwon, S.-W. Kim, and J.-Y. Jang

See editorial on page 475.

The authors document the natural history of BD-IPMN through long-term surveillance and suggest that the surveillance interval must be optimized according to the initial tumor size and growth rate.

Basic and Translational—Alimentary Tract**585 DNA Methylation and Transcription Patterns in Intestinal Epithelial Cells From Pediatric Patients With Inflammatory Bowel Diseases Differentiate Disease Subtypes and Associate With Outcome**

www

K. J. Howell, J. Kraiczy, K. M. Nayak, M. Gasparetto, A. Ross, C. Lee, T. N. Mak, B.-K. Koo, N. Kumar, T. Lawley, A. Sinha, P. Rosenstiel, R. Heuschkel, O. Stegle, and M. Zilbauer

Impaired function of the intestinal epithelium has been implicated in pathogenesis of IBD. Epigenetic and transcriptional profiling of primary human intestinal epithelium revealed distinct disease specific alterations in children newly diagnosed with IBD which correlate with disease outcome.

599 Long Noncoding RNA *uc.173* Promotes Renewal of the Intestinal Mucosa by Inducing Degradation of MicroRNA 195

www

L. Xiao, J. Wu, J.-Y. Wang, H. K. Chung, S. Kalakonda, J. N. Rao, M. Gorospe, and J.-Y. Wang

Findings obtained from in vitro, *ex vivo*, and in vivo systems indicate that long noncoding RNA *uc.173* stimulates regeneration of the intestinal mucosa by reducing microRNA 195 levels.

612 Genome and Methylome Variation in *Helicobacter pylori* With a *cag* Pathogenicity Island During Early Stages of Human Infection

www

S. Nell, I. Estibariz, J. Krebes, B. Bunk, D. Y. Graham, J. Overmann, Y. Song, C. Spröer, I. Yang, T. Wex, J. Korfach, P. Malfertheiner, and S. Suerbaum

The authors analyzed the genome sequences of *Helicobacter pylori* bacteria that had evolved in the stomachs of human volunteers and found that the large amount of genetic variation in *H pylori* poses an important challenge to vaccine development.

624 Transcription and Signaling Regulators in Developing Neuronal Subtypes of Mouse and Human Enteric Nervous System

E www

CCV

F. Memic, V. Knoflach, K. Morarach, R. Sadler, C. Laranjeira, J. Hjerling-Leffler, E. Sundström, V. Pachnis, and U. Marklund

See editorial on page 478.

This study identifies and describes expression of genes with plausible regulatory roles in the generation of different types of enteric neurons in mouse and human embryonic gut.

637 MicroRNAs 15A and 16-1 Activate Signaling Pathways That Mediate Chemotaxis of Immune Regulatory B cells to Colorectal Tumors

www

R. Liu, Z. Lu, J. Gu, J. Liu, E. Huang, X. Liu, L. Wang, J. Yang, Y. Deng, J. Qian, F. Luo, Z. Wang, H. Zhang, X. Jiang, D. Zhang, J. Qian, G. Liu, H. Zhu, Y. Qian, Z. Liu, and Y. Chu

The authors found increased levels of MIR15A and MIR16-1 to reduce numbers of IgA+B cells in colorectal tumor tissues and correlate with increased survival time of patients.

Basic and Translational—Liver**652 Efficacy of NVR 3-778, Alone and In Combination With Pegylated Interferon, vs Entecavir In uPA/SCID Mice With Humanized Livers and HBV Infection**

E www

K. Klumpp, T. Shimada, L. Allweiss, T. Volz, M. Lütgehetmann, G. Hartman, O. A. Flores, A. M. Lam, and M. Dandri

See editorial on page 481.

A capsid assembly modulator (CAM) can potentially block the production of HBV replication products in a mouse model with HBV infected humanized liver. CAM and interferon in combination show higher antiviral activity than previously observed with other antiviral treatments in this model.

663 Pan-Genotype Hepatitis E Virus Replication in Stem Cell-Derived Hepatocellular Systems

www

X. Wu, V. L. Dao Thi, P. Liu, C. N. Takacs, K. Xiang, L. Andrus, J. Gouttenoire, D. Moradpour, and C. M. Rice

Stem cell-derived hepatocyte-like cells are permissive for pan-genotype hepatitis E virus (HEV) infection. These results reinforce the importance of using more physiologically relevant culture systems for HEV studies.

675 Interleukin 35 Expression Correlates With Microvessel Density in Pancreatic Ductal Adenocarcinoma, Recruits Monocytes, and Promotes Growth and Angiogenesis of Xenograft Tumors in Mice

C. Huang, Z. Li, N. Li, Y. Li, A. Chang, T. Zhao, X. Wang, H. Wang, S. Gao, S. Yang, J. Hao, and H. Ren

Tumor-derived IL-35 promotes angiogenesis via recruiting and reprogramming monocytes in pancreatic ductal adenocarcinoma.

689 Mitochondrial Dysfunction, Through Impaired Autophagy, Leads to Endoplasmic Reticulum Stress, Deregulated Lipid Metabolism, and Pancreatitis in Animal Models

G. Biczó, E. T. Vegh, N. Shalbueva, O. A. Mareninova, J. Elperin, E. Lotshaw, S. Gretler, A. Lugea, S. R. Malla, D. Dawson, P. Ruchala, J. Whitelegge, S. W. French, L. Wen, S. Z. Husain, F. S. Gorelick, P. Hegyi, Z. Rakonczay Jr, I. Gukovsky, and A. S. Gukovskaya

Mitochondrial dysfunction and impaired autophagy are prominent in acinar cells during pancreatitis. Normalizing these pathways alleviates disease severity in mouse models.

704 Cathepsin B-Mediated Activation of Trypsinogen in Endocytosing Macrophages Increases Severity of Pancreatitis in Mice

M. Sendler, F.-U. Weiss, J. Golchert, G. Homuth, C. van den Brandt, U. M. Mahajan, L.-I. Partecke, P. Döring, I. Gukovsky, A. S. Gukovskaya, P. R. Wagh, M. M. Lerch, and J. Mayerle

See editorial on page 482.

In pancreatitis, white blood cells eat (engulf) and activate digestive enzymes which fuels the systemic inflammatory process determining severity of the disease. This process could be used for disease specific therapy.

719 Exome-Wide Association Study of Pancreatic Cancer Risk

R. C. Grant, R. E. Denroche, A. Borgida, C. Virtanen, N. Cook, A. L. Smith, A. A. Connor, J. M. Wilson, G. Peterson, N. J. Roberts, A. P. Klein, S. M. Grimmond, A. Biankin, S. Cleary, M. Moore, M. Lemire, G. Zogopoulos, L. Stein, and S. Gallinger

A case-control study of genetic variation in pancreatic cancer confirms the *BRCA2* gene as important and identifies new candidate genes for pancreatic cancer risk.

CONTINUING MEDICAL EDUCATION (CME)/MOC ACTIVITIES

e16 Exam 1: Noninvasive Diagnosis of Pancreatic Cancer Through Detection of Volatile Organic Compounds in Urine

e18 Exam 2: The Role of Anchoring in Working Up Diarrhea: A Practical Teaching Case

e19 Exam 3: Fructan, Rather Than Gluten, Induces Symptoms in Patients With Self-Reported Non-Celiac Gluten Sensitivity

SPECIAL REPORTS

723 Functional Bowel Disorders: A Roadmap to Guide the Next Generation of Research

L. Chang, C. Di Lorenzo, G. Farrugia, F. A. Hamilton, G. M. Mawe, P. J. Pasricha, and J. W. Wiley

736 Cystic Fibrosis Colorectal Cancer Screening Consensus Recommendations

D. Hadjiliadis, A. Khoruts, A. G. Zauber, S. E. Hempstead, P. Maisonneuve, and A. B. Lowenfels, on behalf of the Cystic Fibrosis Colorectal Cancer Screening Task Force

SELECTED SUMMARIES

746 And Now, Death by Proton Pump Inhibitor?

M. Dougherty and E. S. Dellon

748 Just the FRAX: Management of Glucocorticoid-Induced Osteoporosis

B. Wallace, K. G. Saag, J. R. Curtis, and A. K. Waljee

750 **Sternberg's Surgical Pathology, 6th edition**
C. I. Gonzalez Keelan

CORRESPONDENCE

- 752 **Vedolizumab Concentrations in the Breast Milk of Nursing Mothers With Inflammatory Bowel Disease**
M. Julsgaard, J. Kjeldsen, B. M. Bibby, B. Brock, and D. C. Baumgart
- 754 **Hepatitis B Virus Infection and Hepatitis C Virus Treatment in a Large Cohort of Hepatitis C-Infected Patients in the United States**
A. C. Moorman, J. Xing, L. B. Rupp, S. C. Gordon, P. R. Spradling, J. A. Boscarino, M. A. Schmidt, Y. G. Daida, E. H. Teshale, and S. D. Holmberg, For the Chronic Hepatitis Cohort Study Investigators
- 758 **Portal Vein Thromboses in Cirrhosis: To Treat or Not to Treat?**
A. Mancuso, F. Politi, and A. Maringhini
- 758 **Anticoagulation for Portal Vein Thrombosis in Liver Cirrhosis: Not Only Recanalize the Portal Vein**
H. Chen, Y. Lv, and G. Han
- 759 **What Are the Benefits of Anticoagulation for Portal Vein Thrombosis in Individuals With Cirrhosis?**
C. P. Wood and I. A. Rowe
- 760 **Anticoagulation for Portal Vein Thrombosis in Cirrhosis: Selection of Appropriate Patients**
X. Qi, D.-C. Valla, and X. Guo
- 761 **Reply**
F. Violi, D. Pastori, A. Farcomeni, and L. Loffredo
- 762 **Interval Cancers in Colorectal Cancer Screening Programs**
M. Zorzi, G. Capodaglio, and M. Rugge
- 763 **Reply**
M. van der Vlugt, E. Dekker, and P. M. Bossuyt
- 764 **The Fragility of Probiotic *Bifidobacterium longum* NCC3001 Use for Depression in Patients With Irritable Bowel Syndrome**
C. Meyer and M. Vassar
- 764 **Reply**
M. I. Pinto Sanchez, P. Moayyedi, and P. Bercik
- 765 **Endoscopy Examination Time: Longer Is Really Better?**
G.-H. Lo